IM156
Code | Size | Price |
---|
TAR-T8532-1mg | 1mg | £112.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T8532-1mL | 1 mL * 10 mM (in DMSO) | £140.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T8532-5mg | 5mg | £164.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T8532-10mg | 10mg | £205.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T8532-25mg | 25mg | £298.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T8532-50mg | 50mg | £407.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T8532-100mg | 100mg | £571.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
IM156 is an orally bioavailable mitochondrial oxidative phosphorylation (OxPhos) inhibitor, with potential antineoplastic activity.
CAS:
1422365-93-2
Formula:
C13H16F3N5O
Molecular Weight:
315.29
Pathway:
Apoptosis
Purity:
1
SMILES:
FC(F)(F)OC1=CC=C(C=C1)NC(=N)NC(=N)N2CCCC2
Target:
OXPHOS
References
Said Izreig, Alexandra Gariepy, Irem Kaymak, et al. Repression of LKB1 by miR-17?92 Sensitizes MYC-Dependent Lymphoma to Biguanide Treatment.Cell Rep Med. 2020 May 19;1(2):100014.
Son J , Cho Y W , Woo Y J , et al. Metabolic Reprogramming by the Excessive AMPK Activation Exacerbates Antigen-Specific Memory CD8 + T Cell Differentiation after Acute Lymphocytic Choriomeningitis Virus Infection[J]. Immune Network, 2019, 19(2).